A Phase 2 interventional study of Brivaracetam and Lorazepam in Epilepsy, sponsored by UCB Biopharma S.P.R.L.. Completed at 14 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-12-16.
Sponsored by UCB Biopharma S.P.R.L. (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 24th largest by enrollment, is one of 3 that started in 2017, is one of 6 in phase 2, and was the 21st registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2017.
This study's enrollment of 46 is close to the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma S.P.R.L., one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma S.P.R.L. is the lead sponsor of 48 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 82nd largest by enrollment of the 116 interventional ones that give a count, is one of 8 that started in 2017, is one of 26 in phase 2, and was the 107th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV) compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period
Drug: Brivaracetam
Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period
Drug: Brivaracetam
Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.
Drug: Lorazepam
* Pharmaceutical Form: Solution for infusion * Concentration: 10 mg/ml * Route of Administration: intravenous
Also known as: Briviact
* Pharmaceutical Form: Solution for injection * Route of Administration: intravenous
Time to Next Seizure (Per Clinical Observation With Electroencephalogram [EEG] Confirmation) or Rescue Medication
This variable was calculated in hours. The event of next seizure was defined as the first seizure (clinically observed with electroencephalogram \[EEG\] confirmation) with the start date and time within 12 hours after the end of investigational medicinal product (IMP) administration.
Time frame: During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2)
Time to Next Seizure (Per Clinical Observation) or Rescue Medication
This variable was calculated in hours. The event of next seizure was defined as the first seizure (clinically observed and not necessarily confirmed via electroencephalogram \[EEG\]) with the start date and time within 12 hours after the end of investigational medicinal product (IMP) administration.
Time frame: During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2)
Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 6 Hours After the End of Study Drug Administration
This variable was defined as the number of subjects seizure free during 6 hours after the end of study drug administration divided by the number of subjects in the Intent-to-Treat (ITT) set multiplied by 100.
Time frame: At 6 hours after the end of study drug administration
Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 8 Hours After the End of Study Drug Administration
This variable was defined as the number of subjects seizure free during 8 hours after the end of study drug administration divided by the number of subjects in the ITT set multiplied by 100.
Time frame: At 8 hours after the end of study drug administration
Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 12 Hours After the End of Study Drug Administration
This variable was defined as the number of subjects seizure free during 12 hours after the end of study drug administration divided by the number of subjects in the ITT set multiplied by 100.
Time frame: At 12 hours after the end of study drug administration
Percentage of Subjects Who Receive Rescue Medication During the 6 Hours After the End of Study Drug Administration
This variable was defined as the number of subjects who received rescue medication with start date and time within the first 6 hours after the end of study drug administration divided by the number of subjects in the Intent-to-Treat as randomized (ITT-R) set multiplied by 100.
Time frame: During the 6 hours after the end of study drug administration
Percentage of Subjects Who Receive Rescue Medication During the 8 Hours After the End of Study Drug Administration
This variable was defined as the number of subjects who received rescue medication with start date and time within the first 8 hours after the end of study drug administration divided by the number of subjects in the ITT-R set multiplied by 100.
Time frame: During the 8 hours after the end of study drug administration
Percentage of Subjects Who Receive Rescue Medication During the 12 Hours After the End of Study Drug Administration
This variable was defined as the number of subjects who received rescue medication with start date and time within the first 12 hours after the end of study drug administration divided by the number of subjects in the ITT-R set multiplied by 100.
Time frame: During the 12 hours after the end of study drug administration
The study started to enroll patients in February 2017 and concluded in April 2018.
| Milestone | Lorazepam (LZP) | Brivaracetam (BRV) 100 mg | Brivaracetam (BRV) 200 mg |
|---|---|---|---|
| Started | 16 | 15 | 15 |
| Completed | 14 | 15 | 15 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Fall with subsequent nasal fracture | 1 | 0 | 0 |
This variable was calculated in hours. The event of next seizure was defined as the first seizure (clinically observed with electroencephalogram \[EEG\] confirmation) with the start date and time within 12 hours after the end of investigational medicinal product (IMP) administration.
| hours | Lorazepam (LZP) (ITT-R) | Brivaracetam (BRV) 100 mg (ITT-R) | Brivaracetam (BRV) 200 mg (ITT-R) |
|---|---|---|---|
| Time to Next Seizure (Per Clinical Observation With Electroencephalogram [EEG] Confirmation) or Rescue Medication | NA (5.55 to NA) | NA (6.93 to NA) | NA (4.33 to NA) |
This variable was calculated in hours. The event of next seizure was defined as the first seizure (clinically observed and not necessarily confirmed via electroencephalogram \[EEG\]) with the start date and time within 12 hours after the end of investigational medicinal product (IMP) administration.
| hours | Lorazepam (LZP) (ITT-R) | Brivaracetam (BRV) 100 mg (ITT-R) | Brivaracetam (BRV) 200 mg (ITT-R) |
|---|---|---|---|
| Time to Next Seizure (Per Clinical Observation) or Rescue Medication | NA (5.55 to NA) | NA (6.93 to NA) | NA (4.33 to NA) |
This variable was defined as the number of subjects seizure free during 6 hours after the end of study drug administration divided by the number of subjects in the Intent-to-Treat (ITT) set multiplied by 100.
| percentage of participants | Lorazepam (LZP) (ITT-R) | Brivaracetam (BRV) 100 mg (ITT-R) | Brivaracetam (BRV) 200 mg (ITT-R) |
|---|---|---|---|
| Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 6 Hours After the End of Study Drug Administration | 73.3 | 86.7 | 80.0 |
This variable was defined as the number of subjects seizure free during 8 hours after the end of study drug administration divided by the number of subjects in the ITT set multiplied by 100.
| percentage of participants | Lorazepam (LZP) (ITT-R) | Brivaracetam (BRV) 100 mg (ITT-R) | Brivaracetam (BRV) 200 mg (ITT-R) |
|---|---|---|---|
| Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 8 Hours After the End of Study Drug Administration | 73.3 | 80.0 | 80.0 |
This variable was defined as the number of subjects seizure free during 12 hours after the end of study drug administration divided by the number of subjects in the ITT set multiplied by 100.
| percentage of participants | Lorazepam (LZP) (ITT-R) | Brivaracetam (BRV) 100 mg (ITT-R) | Brivaracetam (BRV) 200 mg (ITT-R) |
|---|---|---|---|
| Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 12 Hours After the End of Study Drug Administration | 60.0 | 80.0 | 80.0 |
This variable was defined as the number of subjects who received rescue medication with start date and time within the first 6 hours after the end of study drug administration divided by the number of subjects in the Intent-to-Treat as randomized (ITT-R) set multiplied by 100.
| percentage of participnats | Lorazepam (LZP) (ITT-R) | Brivaracetam (BRV) 100 mg (ITT-R) | Brivaracetam (BRV) 200 mg (ITT-R) |
|---|---|---|---|
| Percentage of Subjects Who Receive Rescue Medication During the 6 Hours After the End of Study Drug Administration | 20.0 | 0 | 6.7 |
This variable was defined as the number of subjects who received rescue medication with start date and time within the first 8 hours after the end of study drug administration divided by the number of subjects in the ITT-R set multiplied by 100.
| percentage of participants | Lorazepam (LZP) (ITT-R) | Brivaracetam (BRV) 100 mg (ITT-R) | Brivaracetam (BRV) 200 mg (ITT-R) |
|---|---|---|---|
| Percentage of Subjects Who Receive Rescue Medication During the 8 Hours After the End of Study Drug Administration | 26.7 | 6.7 | 13.3 |
This variable was defined as the number of subjects who received rescue medication with start date and time within the first 12 hours after the end of study drug administration divided by the number of subjects in the ITT-R set multiplied by 100.
| percentage of participnats | Lorazepam (LZP) (ITT-R) | Brivaracetam (BRV) 100 mg (ITT-R) | Brivaracetam (BRV) 200 mg (ITT-R) |
|---|---|---|---|
| Percentage of Subjects Who Receive Rescue Medication During the 12 Hours After the End of Study Drug Administration | 40.0 | 6.7 | 13.3 |
Collected over From Screening, at Day -28 and up to Safety Follow-Up (24 hours after the end of drug administration).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lorazepam (LZP) (ITT-T) | 0/16 (0%) | 1/16 (6.3%) | 4/16 (25%) |
| Brivaracetam (BRV) 100 mg (ITT-T) | 0/15 (0%) | 0/15 (0%) | 6/15 (40%) |
| Brivaracetam (BRV) 200 mg (ITT-T) | 0/15 (0%) | 0/15 (0%) | 3/15 (20%) |
| Event | Lorazepam (LZP) (ITT-T) | Brivaracetam (BRV) 100 mg (ITT-T) | Brivaracetam (BRV) 200 mg (ITT-T) |
|---|---|---|---|
| Seizure clusterNervous system disorders | 1/16 | 0/15 | 0/15 |
| Event | Lorazepam (LZP) (ITT-T) | Brivaracetam (BRV) 100 mg (ITT-T) | Brivaracetam (BRV) 200 mg (ITT-T) |
|---|---|---|---|
| DizzinessNervous system disorders | 0/16 | 3/15 | 1/15 |
| NauseaGastrointestinal disorders | 0/16 | 2/15 | 2/15 |
| HeadacheNervous system disorders | 1/16 | 2/15 | 0/15 |
| SedationNervous system disorders | 2/16 | 0/15 | 1/15 |
| SomnolenceNervous system disorders | 2/16 | 0/15 | 0/15 |
| Atrioventricular dissociationCardiac disorders | 0/16 | 1/15 | 0/15 |
| TachycardiaCardiac disorders | 0/16 | 1/15 | 0/15 |
| VertigoEar and labyrinth disorders | 0/16 | 1/15 | 0/15 |
| VomitingGastrointestinal disorders | 0/16 | 0/15 | 1/15 |
| Vessel puncture site painGeneral disorders | 0/16 | 1/15 | 0/15 |
Baseline Characteristics refer to the Intent-to-Treat as Treated Set which consisted of subjects who were treated with investigational medicinal product (IMP) regardless of qualifying seizure status.
| Age, Categorical(Participants) | Lorazepam (LZP) | Brivaracetam (BRV) 100 mg | Brivaracetam (BRV) 200 mg | Total Title |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 1 | 1 |
| Between 18 and 65 years | 16 | 14 | 13 | 43 |
| >=65 years | 0 | 1 | 1 | 2 |
| Age, Continuous(years) | Lorazepam (LZP) | Brivaracetam (BRV) 100 mg | Brivaracetam (BRV) 200 mg | Total Title |
|---|---|---|---|---|
| Mean | 41.10 ± 11.18 | 43.92 ± 12.41 | 41.59 ± 15.98 | 42.18 ± 13.06 |
| Sex: Female, Male(Participants) | Lorazepam (LZP) | Brivaracetam (BRV) 100 mg | Brivaracetam (BRV) 200 mg | Total Title |
|---|---|---|---|---|
| Female | 11 | 8 | 4 | 23 |
| Male | 5 | 7 | 11 | 23 |
| Race/Ethnicity, Customized(Participants) | Lorazepam (LZP) | Brivaracetam (BRV) 100 mg | Brivaracetam (BRV) 200 mg | Total Title |
|---|---|---|---|---|
| Asian | 0 | 1 | 1 | 2 |
| Black or African American | 4 | 2 | 2 | 8 |
| White | 12 | 12 | 12 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Feb 2017 to primary completion in Apr 2018, 14 months.
Results were first posted in May 2019, 1 year 1 month after primary completion.
Of 45 industry-sponsored phase 2 interventional studies under Epilepsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 14 months is below that.
Counting every sponsor, half of 66 studies reached it within 23 months; a quarter within 14 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam